COVID 19 is now a global pandemic.The cases of coronavirus are increasing rapidly across the world with the count crossing 349,980 globally and increasing every day. The virus, which originated from China, has rapidly spread to about 160 countries.This is a critical time for information, support and reassurance that science and evidence can offer. We are talking to infectious disease expert Dr. Steven Pergam on where we stand and what to expect in terms of safety for immunocompromised patients, effectiveness of social distancing, preparing and responding to the pandemic in our daily lives.
CLR 131 is a targeted small-molecule that is being developed for the treatment of myeloma and lymphoma, as well as pediatric and head & neck cancers. It works by delivering a radioactive, toxic compound directly to tumor cells, while limiting exposure to healthy cells. CLR 131 was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission. We are talking to Dr. Sikander Ailawadhi, the lead investigator on several CLR 131 trials, to get his perspective on the potential and future of CLR 131 as an important addition to myeloma treatments.
Brain tumors can be among the most challenging cancers to treat. The blood-brain barrier, a natural defense mechanism that shields the brain from harm can also prevent cancer treatments from reaching tumors. However, immunotherapy, precision medicine, and the other new approaches to treatments have been able to get through these barriers and effectively reach tumors. We are discussing the latest in brain tumor research and treatment with neuro-oncologist Dr. Nancy Bush from UCSF Helen Diller Family Comprehensive Cancer Center.
Panelists
Dr. Nancy Bush
Adam Hayden
Jeremy Pivor
Priya Menon
For any of the talks dial-in to 718-664-6574 to participate and ask a question LIVE On-Air! Only 50 callers permitted at one time so HURRY!
👨🏻💼FROM THE CEO’s DESK “As we wrap up 2022, we are pleased to see 12 million+ actions taken by patients, researchers and study sponsors across all our platforms to support clinical research. This includes hundreds of…
Diversity in clinical trials is crucial to understanding the effectiveness of drugs in different ethnic populations. The inclusion of participants from different races and ethnicity also ensures the generalization of the result and helps achieve health…
Are you ready to challenge yourself and push the boundaries of what you think is possible? Join us for our year-end hackathon and prompt-a-thon, where you’ll have the opportunity to work with a team of like-minded…